

## **CHQ Pharmacy Service**

## MEDICATION PATIENT SAFETY COMMUNIQUÉ

Subject:	CADD Solis pump being removed from Children's Hospital Queensland (CHQ) at Home Service		
Purpose of this Notice:	To inform all CHQ staff of temporary changes in medication administration for Hospital in the Home (HITH) patients and guide prescribing.		
Issued by:	Dr Katie Davies CHQ at Home Medical Lead and Dr Alyssa Courtney CHQ at Home Senior Medical Officer  Samantha Peterson, CHQ at Home Nurse Unit Manager	Issue Date:	13/12/24
	Dr Sonya Stacey, Director of Pharmacy		
	Director of Infection Management and prevention service		
Issue and Impact within CHQ:	Issue: Ongoing issues have been identified with air in CADD Solis Pump lines for CHQ at Home patients. Whilst these pumps may be used in other areas of the hospital in different ways this document is specifically for patients under Hospital in the Home (HITH).		
	Action Taken: CADD Solis pumps are not currently in use in the HITH setting whilst a being investigated. In the interim, the HITH registrar will liaise with the patient's treating te appropriate option, in consultation with the Infectious Diseases team we Consideration should be made for the following:	am to conside	er an
	<ul> <li>Whether an alternative medication choice that is administered for use (e.g,ceftriaxone) based on patient's condition and micr</li> </ul>		
	<ul> <li>Utilise elastomeric infusors where feasible for patients who are short term patients being admitted to <u>CHQ at Home via ED pa</u> Note: Elastomeric infusors need to be weighed by HITH nursir connection and disconnection to <u>monitor infusor function</u>.</li> </ul>	thway on cefa	azolin).
	<ul> <li>Consider use of AMBiT pump for continuous infusions or constherapy in consultation with the Infectious diseases team, for pacteraemic or those with invasive infections, patients with cysimmunocompromised patients or those with small lines that we elastomeric to infuse sufficiently (e.g. &gt;22 gauge cannula).</li> </ul>	patients who a stic fibrosis,	are
	<ul> <li>Alternative pumps are being investigated and may be trialled in accordance with CHQ guidelines</li> </ul>	n the future in	
Target Audience:	CHQ staff involved in the review/care of HITH patients.		
Action Required:	Share this communique with your team and discuss at the next team hincrease awareness of this change.	iuddle/meetin	g to





Action Officers:	Notify any issues by phoning the CHQ at Home NUM (0472 862 729).
	Calls can then be referred to:
	CHQ at Home Fellow/ Registrar or CHQ at Home Pharmacist 0437 976 230 (business hours).
	CHQ Infectious diseases team via QCH Switchboard (business hours – ID registrar, afterhours – ID SMO on service).
	CHQ On call pharmacist via QCH Switchboard (afterhours)
Further information:	Document author: Madelyne Bernhardt, CHQ at Home Pharmacist